Jade Biosciences (JBIO) EBITDA (2020 - 2026)
Jade Biosciences' (JBIO) quarterly EBITDA came in at -$43.4 million in Q1 2026, down 85.79% YoY from -$305.7 million in Q1 2025, and down 24.2% on a QoQ basis from -$35.0 million in Q4 2025.
Jade Biosciences (JBIO) EBITDA (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of EBITDA data on file, last reported at -$43.4 million in Q1 2026.
- Quarterly EBITDA fell 85.79% year-over-year to -$43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.6 million (down 32.75% YoY) and the FY2025 annual result came in at -$113.5 million, down 52.21% from the prior year.
- EBITDA eased to -$43.4 million in Q1 2026, from -$35.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$11.0 million in Q1 2022 to a low of -$43.4 million in Q1 2026.
- A 5-year average of -$23.1 million and a median of -$22.1 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 296.37% — and 2024, when it grew 27.2%.
- Tracing JBIO's EBITDA over 5 years: stood at -$15.9 million in 2022, then plunged by 39.2% to -$22.1 million in 2023, then plunged by 61.05% to -$35.5 million in 2024, then rose by 1.57% to -$35.0 million in 2025, then slipped by 24.2% to -$43.4 million in 2026.
- The last three EBITDA figures came in at -$43.4 million (Q1 2026), -$35.0 million (Q4 2025), and -$27.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | -58.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.92 Mn |
| Mar 31, 2026 | -43.45 Mn |
| Dec 31, 2025 | -34.98 Mn |
| Sep 30, 2025 | -27.40 Mn |
| Jun 30, 2025 | -27.78 Mn |
| Mar 31, 2025 | -23.38 Mn |
| Dec 31, 2024 | -35.54 Mn |
| Sep 30, 2024 | -15.56 Mn |
| Jun 30, 2024 | -26.17 Mn |
| Mar 31, 2024 | -24.62 Mn |
| Dec 31, 2023 | -22.07 Mn |
| Sep 30, 2023 | -21.37 Mn |
| Jun 30, 2023 | -20.34 Mn |
| Mar 31, 2023 | -17.64 Mn |
| Dec 31, 2022 | -15.85 Mn |
| Sep 30, 2022 | -14.15 Mn |
| Jun 30, 2022 | -12.22 Mn |
| Mar 31, 2022 | -11.02 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -6.20 Mn |